AK 0529

Drug Profile

AK 0529

Alternative Names: AK0529

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Ark Biosciences
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers, In adults) in Australia (PO, Capsule)
  • 10 Oct 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in China (PO) (NCT03322800)
  • 28 Jun 2016 Ark Biosciences terminates phase I trial in Respiratory syncytial virus infections (In infants) in Australia (NCT02460016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top